Subcutaneous administration of ADAMTS13
This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
1. A method for treating thrombotic thrombocytopenic purpura (TTP) in a mammal, the method comprising subcutaneously administering a therapeutically effective amount of a composition comprising isolated a disintegrin and metalloproteinase with thrombospondin type I motifs 13 (ADAMTS13) to the mammal in need thereof, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 40% as compared to intravenous administration normalized for the same dose, and thereby treating TTP in the mammal.
2. The method of claim 1 , wherein the TTP is inherited TTP.
3. The method of claim 1 , wherein the TTP is acquired TTP.
4. The method of claim 1 , wherein the bioavailability of the ADAMTS13 after subcutaneous administration is 40-80%, 45-80%, 50-80%, 55-80%, 60-80%, 65-80%, 70-80% or 75-80% as compared to intravenous administration normalized for the same dose.
5. The method of claim 2 , wherein the therapeutically effective amount is from 20 to 160 activity units per kilogram body weight.
6. The method of claim 3 , wherein the therapeutically effective amount is from 40 to 2,000 activity units per kilogram body weight.
7. The method of claim 1 , wherein the ADAMTS13 is administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, every 12 hours, every 8 hours, every six hours, every four hours, or every two hours.
8. The method of claim 1 , wherein the ADAMTS13 is recombinant.
9. The method of claim 1 , wherein the ADAMTS13 is plasma derived.
10. The method of claim 1 , wherein the mammal is a human.
11. The method of claim 1 , wherein the composition is a stable aqueous solution ready for administration.
12. The method of claim 1 , wherein the composition is reconstituted from a lyophilized composition with a pharmaceutically acceptable vehicle suitable for injection.
13. A method for treating a bleeding episode associated with an increase in blood clotting activity associated with thrombotic thrombocytopenic purpura TTP in a mammal, the method comprising subcutaneously administering a therapeutically effective amount of a composition comprising isolated a disintegrin and metalloproteinase with thrombospondin type I motifs 13 (ADAMTS13) to the mammal in need thereof, wherein the therapeutically effective amount of ADAMTS13 is from 20 to 4,000 activity units per kilogram body weight, and wherein the ADAMTS13 has a bioavailability of at least 40% after subcutaneous administration as compared to intravenous administration normalized for the same dose, thereby treating said bleeding episode associated with an increase in blood clotting activity associated with TTP.
14. The method of claim 13 , wherein the TTP is inherited TTP and the standard intravenous dose is from about 10 to about 80 activity units per kilogram body weight.
15. The method of claim 13 , wherein the TTP is acquired TTP and the standard intravenous dose is from about 20 to about 1,000 activity units per kilogram body weight.
16. The method of claim 13 , wherein the ADAMTS13 has a bioavailability of 40-80%, 45-80%, 50-80%, 55-80%, 60-80%, 65-80%, 70-80% or 75-80% after subcutaneous administration as compared to intravenous administration normalized for the same dose.
17. The method of claim 13 , wherein the ADAMTS13 is administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, every 12 hours, every 8 hours, every six hours, every four hours, or every two hours.
18. The method of claim 13 , wherein the mammal is a human.
19. The method of claim 13 , wherein the composition is a stable aqueous solution ready for administration.
20. The method of claim 13 , wherein the composition is reconstituted from a lyophilized composition with a pharmaceutically acceptable vehicle suitable for injection.
21. The method of claim 2 , wherein the therapeutically effective amount is from about 40 to about 200 activity units per kilogram body weight.
22. The method of claim 2 , wherein the therapeutically effective amount is from about 20 to about 500 activity units per kilogram body weight.
23. The method of claim 2 , wherein the therapeutically effective amount is from about 40 to about 500 activity units per kilogram body weight.
24. The method of claim 2 , wherein the therapeutically effective amount is from about 20 to about 1,000 activity units per kilogram body weight.
25. The method of claim 2 , wherein the therapeutically effective amount is from about 40 to about 1,000 activity units per kilogram body weight.
26. The method of claim 3 , wherein the therapeutically effective amount is from about 80 to about 2,000 activity units per kilogram body weight.
27. The method of claim 3 , wherein the therapeutically effective amount is from about 100 to about 2,000 activity units per kilogram body weight.
28. The method of claim 3 , wherein the therapeutically effective amount is from about 40 to about 1,000 activity units per kilogram body weight.
29. The method of claim 3 , wherein the therapeutically effective amount is from about 80 to about 1,000 activity units per kilogram body weight.
30. The method of claim 3 , wherein the therapeutically effective amount is from about 100 to about 1,000 activity units per kilogram body weight.